BIOFILCHEM2024-04-012024-06-30 BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member BIOFILCHEM2024-06-30 BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue01Member BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue02Member BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults01Member BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults02Member BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets01Member BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets02Member BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOFILCHEM2024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOFILCHEM2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member BIOFILCHEM2024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524396 BIOFILCHEM NOTLISTED Biofil Chemicals & Pharmaceuticals Limited Equity 2024-04-01 2025-03-31 2024-08-13 2024-08-08 INR Lakhs First quarter 17:00:00 18:20:00 2024-08-13 2024-08-13 Not applicable Multi segment 2024-04-01 2024-06-30 Unaudited Standalone 84434000.00 294000.00 84728000.00 6862000.00 74301000.00 -4008000.00 1386000.00 107000.00 987000.00 2813000.00 82448000.00 2280000.00 0.00 2280000.00 587000.00 0.00 587000.00 0.00 1693000.00 0.00 0.00 0.00 0.00 1693000.00 0.00 1693000.00 0.00 0.00 162738000.00 10 0.10 0.10 0.00 0.00 0.10 0.10 1 The above Un-Audited Financial Results for the Quarter ended June 30, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 13-08-2024. The above results have been reviewed by Statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs. 2 This financial results has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. 3 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary. 4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments a. Pharma Product b. Chemicals Division 5 The aforesaid un-audited Financial Results will be uploaded on the Company’s website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors 6 The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review. Date : 13/08/2024 FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED Place : Indore RAMESH SHAH CHAIRMAN & MANAGING DIRECTOR ( DIN: 00028819) Other Expenses 2813000.00 Chemical Division 10471000.00 Pharma Division 73963000.00 84434000.00 0.00 84434000.00 Chemical Division 2171000.00 Pharma Division 195000.00 2366000.00 86000.00 0.00 2280000.00 Chemical Division 213596000.00 Pharma Division 292755000.00 506351000.00 Chemical Division 87817000.00 Pharma Division 230672000.00 318489000.00 0.00 0.00